A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Public ClinicalTrials.gov record NCT06254495. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label Study to Evaluate PF-08046044/SGN-35C in Adults With Advanced Malignancies.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.
Study identification
- NCT ID
- NCT06254495
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2024
- Primary completion
- Apr 12, 2026
- Completion
- Apr 12, 2026
- Last update posted
- Jul 5, 2026
2024 – 2026
United States locations
- U.S. sites
- 27
- U.S. states
- 7
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope (City of Hope National Medical Center, City Of Hope Medical Center) | Duarte | California | 91010 | — |
| IP Address: City of Hope Investigational Drug Services(IDS) | Duarte | California | 91010 | — |
| University of California, San Francisco Medical Center | San Francisco | California | 94143 | — |
| Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center | Coral Gables | Florida | 33146 | — |
| University of Miami Hospital and Clinics - Deerfield Beach | Deerfield Beach | Florida | 33442 | — |
| Sylvester Comprehensive Cancer Center - Hollywood | Hollywood | Florida | 33021 | — |
| Griffin Cancer Research Building (GCRB) | Miami | Florida | 33136 | — |
| University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| University Of Miami Hospitals And Clinics | Miami | Florida | 33136 | — |
| Sylvester Comprehensive Cancer Center - Kendall | Miami | Florida | 33176 | — |
| The University of Kansas Cancer Center, Investigational Drug Services | Fairway | Kansas | 66205 | — |
| University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | — |
| The University of Kansas Hospital Cambridge North Tower A | Kansas City | Kansas | 66160 | — |
| The University of Kansas Hospital | Kansas City | Kansas | 66160 | — |
| The University of Kansas Medical Center Medical Office Building | Kansas City | Kansas | 66160 | — |
| The University of Kansas Cancer Center - Overland Park | Overland Park | Kansas | 66210 | — |
| The University of Kansas Cancer Center - Indian Creek Campus | Overland Park | Kansas | 66211 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| The University of Kansas Cancer Center - Lee's Summit | Lee's Summit | Missouri | 64064 | — |
| Nebraska Medicine - Bellevue Medical Center | Bellevue | Nebraska | 68123 | — |
| Nebraska Medical Center | Omaha | Nebraska | 68105 | — |
| Nebraska Medicine - Village Pointe | Omaha | Nebraska | 68118 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Robert Wood Johnson University Hospital | New Brunswick | New Jersey | 08901 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Fred Hutchinson Cancer Research Center | Seattle, WA | Seattle | Washington | 98109 | — |
| University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06254495, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 5, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06254495 live on ClinicalTrials.gov.